Drug name - Leqvio

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9074213 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Mar, 2022

(6 months ago)

US8546143 NOVARTIS Compositions and methods for inhibiting expression of a target gene
Apr, 2022

(5 months ago)

US8232383 NOVARTIS RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
Feb, 2023

(4 months from now)

US11078485 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Nov, 2023

(1 year, 1 month from now)

US9708610 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Jan, 2024

(1 year, 2 months from now)

US10669544 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

US9708615 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

US10273477 NOVARTIS Therapeutic compositions
Mar, 2024

(1 year, 5 months from now)

US8809292 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
May, 2027

(4 years from now)

US10131907 NOVARTIS Glycoconjugates of RNA interference agents
Aug, 2028

(5 years from now)

US10806791 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

US9370582 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

US8828956 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(6 years from now)

US8106022 NOVARTIS Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(7 years from now)

US10125369 NOVARTIS PCSK9 iRNA compositions and methods of use thereof
Aug, 2034

(11 years from now)

CN1312856A NOVARTIS Enzymatic Nucleic Acid Treatment Of Diseases Or Conditions Associated With Hepatitis C Virus Infection
Nov, 2004

(17 years ago)

CN1630724A NOVARTIS Method For Inhibiting Expression Of Target Gene
Jan, 2007

(15 years ago)

CN1608131A NOVARTIS Medicine For Treating Pancreatic Cancer
Jan, 2009

(13 years ago)

CN1608133A NOVARTIS Double-Stranded Ribonucleic Acid For Treating Positive (+) Chain Rna Virus Infection Of Suffers
Sep, 2009

(13 years ago)

CN1604783A NOVARTIS The Medicine For Treating Fibrosis Disease By Rna Interference
Dec, 2009

(12 years ago)

CN1650010A NOVARTIS Method For Inhibiting Expression Of Target Gene And Medicine For Treating Tumour Disease
Jan, 2010

(12 years ago)

CN101605892A NOVARTIS Rna Interference Mediated Inhibition Of Hepatitis C Virus
Aug, 2012

(10 years ago)

CN102124107A NOVARTIS Rna Interference Mediated Inhibition Of Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Gene Expression Using Short Interfering Nucleic Acid (Sina)
May, 2013

(9 years ago)

CN101426912A NOVARTIS Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference
Jun, 2013

(9 years ago)

CN102006890A NOVARTIS Targeting Lipid
Oct, 2015

(6 years ago)

CN101484588B NOVARTIS Composition And Method For Inhibiting The Expression Of The Pcsk9 Gene
May, 2019

(3 years ago)

CN101484588A NOVARTIS Composition And Method For Inhibiting The Expression Of The Pcsk9 Gene
May, 2019

(3 years ago)

CN1835897A NOVARTIS Manufacturing A Sintered Refractory Product Having Improved Foaming Properties For Blank
Aug, 2024

(1 year, 10 months from now)

CN1835897B NOVARTIS Manufacturing With Improved Foaming Properties Of The Sintered Refractory Product For Blank
Aug, 2024

(1 year, 10 months from now)

CN104854242A NOVARTIS Pcsk9 Irna Composition And Using Method Thereof
Dec, 2033

(11 years from now)

CN104854242B NOVARTIS Pcsk9 Irna Composition And Using Method Thereof
Dec, 2033

(11 years from now)

IN200300537P3 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN213846B NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN200300572P3 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

IN203882B NOVARTIS Method For Inhibiting The Expression Of A Targe Gene
Jan, 2022

(8 months ago)

IN200806166P4 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

IN269138B NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

IN368763B NOVARTIS Pcsk9 Irna Compositions And Methods Of Use Thereof
Dec, 2033

(11 years from now)

IN201503007P4 NOVARTIS Pcsk9 Irna Compositions And Methods Of Use Thereof
Dec, 2033

(11 years from now)

EP748382B1 NOVARTIS Non-Nucleotide Containing Enzymatic Nucleic Acid
Aug, 2014

(8 years ago)

EP748382A1 NOVARTIS Non-Nucleotide Containing Enzymatic Nucleic Acid
Aug, 2014

(8 years ago)

EP725788B1 NOVARTIS 2'-Amido And 2'-Peptido Modified Oligonucleotides
Oct, 2014

(7 years ago)

EP725788A1 NOVARTIS 2'-Amido And 2'-Peptido Modified Oligonucleotides
Oct, 2014

(7 years ago)

EP728205B1 NOVARTIS Reagent For Treatment Of Arthritic Conditions
Nov, 2014

(7 years ago)

EP728205A1 NOVARTIS Reagent For Treatment Of Arthritic Conditions
Nov, 2014

(7 years ago)

EP1408111A3 NOVARTIS Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor
Oct, 2016

(5 years ago)

EP1408111B1 NOVARTIS Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor
Oct, 2016

(5 years ago)

EP1408111A2 NOVARTIS Method And Reagent For The Treatment Of Diseases Or Conditions Related To Levels Of Vascular Endothelial Growth Factor Receptor
Oct, 2016

(5 years ago)

EP928290B9 NOVARTIS Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP928290A4 NOVARTIS Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP928290A1 NOVARTIS Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP928290B1 NOVARTIS Oligoribonucleotides And Ribonucleases For Cleaving Rna
Jun, 2017

(5 years ago)

EP1214945A2 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1214945A3 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP2363479B1 NOVARTIS Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene
Jan, 2020

(2 years ago)

EP1214945B2 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1550719B1 NOVARTIS Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1214945B1 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1550719A1 NOVARTIS Doublestranded Rna (Dsrna) For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP2363479A1 NOVARTIS Oligoribonucucleotide For Inhibiting The Expression Of A Predefined Gene
Jan, 2020

(2 years ago)

EP1144623A1 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1144623B9 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1144623B1 NOVARTIS Method And Medicament For Inhibiting The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1798285B1 NOVARTIS Methods And Medicament For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1798285A1 NOVARTIS Methods And Medicament For Inhibition The Expression Of A Defined Gene
Jan, 2020

(2 years ago)

EP1349927B1 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease
May, 2021

(1 year, 4 months ago)

EP1349927A2 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicament For Treating A Tumor Disease
May, 2021

(1 year, 4 months ago)

EP1352061A2 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061B9 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP1352061B1 NOVARTIS Method For Inhibiting The Expression Of A Target Gene
Jan, 2022

(8 months ago)

EP2213736B1 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2213736A3 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2213736A2 NOVARTIS Method For Inhibiting The Expression Of A Target Gene And Medicine For Treating A Tumour Illness
Jan, 2022

(8 months ago)

EP2415486B1 NOVARTIS Conjugates And Compositions For Cellular Delivery
May, 2022

(4 months ago)

EP2415486A2 NOVARTIS Conjugates And Compositions For Cellular Delivery
May, 2022

(4 months ago)

EP2415486A3 NOVARTIS Conjugates And Compositions For Cellular Delivery
May, 2022

(4 months ago)

EP1423404A2 NOVARTIS Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423404A4 NOVARTIS Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423404B1 NOVARTIS Rna Interference Mediated Treatment Of Alzheimer'S Disease Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2278004A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287305A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1458741B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
Feb, 2023

(4 months from now)

EP2902406A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1572128B1 NOVARTIS Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1458741A2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
Feb, 2023

(4 months from now)

EP2287305B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287306B2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1572128A4 NOVARTIS Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287305B2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287306A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1572128A2 NOVARTIS Rna Interference Mediated Inhibition Of Hiv Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406A4 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2902406B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1458741A4 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid
Feb, 2023

(4 months from now)

EP3354656A1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406A2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1430157A4 NOVARTIS Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1430157B1 NOVARTIS Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP3354656B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1423406B2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1430157A2 NOVARTIS Rna Interference Mediated Inhibition Of Hepatitis C Virus (Hcv) Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2287306B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP2278004B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Short Interfering Nucleic Acid (Sina)
Feb, 2023

(4 months from now)

EP1560840A4 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP1562971A4 NOVARTIS Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP1560840A2 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP1562971B1 NOVARTIS Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP1560840B1 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP2957568B1 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP2957568A1 NOVARTIS Compositions Comprising Alternating 2'-Modified Nucleosides For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP1562971A2 NOVARTIS Polycyclic Sugar Surrogate-Containing Oligomeric Compounds And Compositions For Use In Gene Modulation
Nov, 2023

(1 year, 1 month from now)

EP1605978A2 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978A4 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407B1 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1605978B1 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407A3 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP2216407A2 NOVARTIS Therapeutic Compositions
Mar, 2024

(1 year, 5 months from now)

EP1615611A2 NOVARTIS Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1615611A4 NOVARTIS Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1615611B1 NOVARTIS Irna Conjugates
Apr, 2024

(1 year, 6 months from now)

EP1620544A4 NOVARTIS Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1620544A2 NOVARTIS Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1620544B1 NOVARTIS Modified Irna Agents
Apr, 2024

(1 year, 6 months from now)

EP1622572A2 NOVARTIS Conjugates And Compositions For Cellular Delivery
Apr, 2024

(1 year, 6 months from now)

EP1622572B1 NOVARTIS Conjugates And Compositions For Cellular Delivery
Apr, 2024

(1 year, 6 months from now)

EP1622572A4 NOVARTIS Conjugates And Compositions For Cellular Delivery
Apr, 2024

(1 year, 6 months from now)

EP1627061B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
May, 2024

(1 year, 7 months from now)

EP1627061A2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (Sina)
May, 2024

(1 year, 7 months from now)

EP1765074A4 NOVARTIS Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1765074B1 NOVARTIS Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1765074A2 NOVARTIS Positionally Modified Sirna Constructs
Jun, 2024

(1 year, 8 months from now)

EP1667944B1 NOVARTIS Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour
Aug, 2024

(1 year, 10 months from now)

EP1667944A1 NOVARTIS Hollow Piece For Producing A Sintered Refractory Product Exhibiting Improved Bubbling Behaviour
Aug, 2024

(1 year, 10 months from now)

EP1664299A1 NOVARTIS Rna Interference Mediated Inhibition Of Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Sep, 2024

(1 year, 11 months from now)

EP1664299B1 NOVARTIS Rna Interference Mediated Inhibition Of Vascular Endothelial Growth Factor And Vascular Endothelial Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid (Sina)
Sep, 2024

(1 year, 11 months from now)

EP1677822B1 NOVARTIS 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1677822A2 NOVARTIS 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1677822A4 NOVARTIS 4'-Thionucleosides And Oligomeric Compounds
Sep, 2024

(1 year, 11 months from now)

EP1713915A2 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina)
Feb, 2025

(2 years from now)

EP1713915B1 NOVARTIS Rna Interference Mediated Inhibition Of Gene Expression Using Multifunctional Short Interfering Nucleic Acid (Multifunctional Sina)
Feb, 2025

(2 years from now)

EP1799270B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes
Sep, 2025

(2 years from now)

EP1799270A2 NOVARTIS Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes
Sep, 2025

(2 years from now)

EP1799270A4 NOVARTIS Compositions And Methods For Inhibiting Expression Of Anti-Apoptotic Genes
Sep, 2025

(2 years from now)

EP1931781B1 NOVARTIS Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference
Aug, 2026

(3 years from now)

EP1931781A2 NOVARTIS Chemically Modified Short Interfering Nucleic Acid Molecules That Mediate Rna Interference
Aug, 2026

(3 years from now)

EP2584047B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3249052B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2584048A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2835429B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3578656A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2835429A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2194128B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3578656B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2194128A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2584048B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2584047A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3249052A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2231195B1 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

EP2231194A2 NOVARTIS Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP2231194B1 NOVARTIS Folate-Irna Conjugates
Dec, 2028

(6 years from now)

EP3156077A1 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

EP3156077B1 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

EP2231195A2 NOVARTIS Targeting Lipids
Dec, 2028

(6 years from now)

EP2929031B9 NOVARTIS Pcsk9 Irna Compositions And Methods Of Use Thereof
Dec, 2033

(11 years from now)

EP2929031A1 NOVARTIS Pcsk9 Irna Compositions And Methods Of Use Thereof
Dec, 2033

(11 years from now)

EP2929031B1 NOVARTIS Pcsk9 Irna Compositions And Methods Of Use Thereof
Dec, 2033

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266825 NOVARTIS Compositions comprising alternating 2′-modified nucleosides for use in gene modulation Nov, 2023

(1 year, 1 month from now)

US8222222 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene Dec, 2027

(5 years from now)

US10851377 NOVARTIS Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder Aug, 2036

(13 years from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.